

1 **Using genetic variants to evaluate the causal effect of cholesterol**
2 **lowering on head and neck cancer risk: a Mendelian randomization**
3 **study**

4 Mark Gormley^{1,2,3*}, James Yarmolinsky^{1,3}, Tom Dudding^{1,2,3}, Kimberley Burrows^{1,3}, Richard M
5 Martin^{1,3,4}, Steven Thomas^{2,4}, Jessica Tyrrell⁵, Paul Brennan⁶, Miranda Pring², Stefania
6 Boccia^{7,8}, Andrew F Olshan⁹, Brenda Diergaard¹⁰, Rayjean J. Hung^{11,12}, Geoffrey Liu^{12,13},
7 Danny Legge¹⁴, Eloiza H Tajara¹⁵, Patricia Severino¹⁶, Martin Lacko¹⁷, Andrew R Ness⁴,
8 George Davey Smith^{1,3}, Emma E Vincent^{1,3,14&}, Rebecca C Richmond^{1,3&}

9 ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
10 University of Bristol, Bristol, UK.

11 ² Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

12 ³ Department of Population Health Sciences, Bristol Medical School, University of Bristol,
13 Bristol, UK.

14 ⁴ National Institute for Health Research Bristol Biomedical Research Centre at the University
15 Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

16 ⁵ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

17 ⁶ Genetic Epidemiology Group, World Health Organization, International Agency for
18 Research on Cancer, Lyon, France.

19 ⁷ Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma,
20 Italy.

21 ⁸ Department of Woman and Child Health and Public Health, Public Health Area, Fondazione
22 Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

23 ⁹ Department of Epidemiology, Gillings School of Global Public Health, University of North
24 Carolina, US.

25 ¹⁰ Department of Human Genetics, Graduate School of Public Health, University of
26 Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US.

27 ¹¹ Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research
28 Institute, Sinai Health System, Toronto, Canada.

29

30 ¹² Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

31 ¹³ Princess Margaret Cancer Centre, Toronto Canada.

32 ¹⁴ School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

33 ¹⁵ School of Medicine of São José do Rio Preto, São Paulo, Brazil.

34 ¹⁶ Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São
35 Paulo, Brazil.

36 ¹⁷ Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute
37 GROW, Maastricht University Medical Center, Maastricht, The Netherlands.

38 **Corresponding author**

39 * Email: mark.gormley@bristol.ac.uk

40

41 **Author contributions**

42 & These authors also contributed equally to this work.

43 E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study
44 and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head
45 and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained
46 through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D.,
47 R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by
48 R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided
49 expertise on both observational and genetic epidemiological methodology and analysis. The
50 initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B.,
51 R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D, R.J.H., G.L., D.L., E.H.T., P.S., M.L.,
52 A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and
53 critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T.,
54 A.R.N and G.D.S.

55

56

57 **Abbreviations:** HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC,
58 oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS,
59 genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal
60 component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-
61 PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic
62 Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA
63 reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester
64 transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density
65 lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
66 lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW,
67 inverse variance weighted; CI, confidence intervals; P, *p*-value.

68

69

70

71

72

73

74

75

76 **Abstract**

77 **Introduction**

78 Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral
79 cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to
80 reduce disease burden include discovery of novel therapies and repurposing of existing
81 drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting
82 HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin
83 use may reduce HNSCC risk. We appraised the relationship of genetically-proxied
84 cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and
85 oropharyngeal (OPC) cancer risk.

86

87 **Methods and findings**

88 We conducted two-sample Mendelian randomization (MR). For the primary analysis,
89 germline genetic variants in *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* were used to proxy the
90 effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary
91 analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide
92 association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary
93 analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies
94 on OC and OPC risk.

95

96 The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and
97 6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

98 cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses
99 combined in a fixed-effects meta-analysis.

100

101 We found limited evidence of a causal effect of genetically-proxied LDL-C lowering
102 using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk.
103 Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in
104 LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8,
105 $p = 9.31 \times 10^{-05}$), with good concordance between GAME-ON and UK Biobank ($I^2 = 22\%$).
106 Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR
107 1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C
108 equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7,
109 95%CI 0.5, 1.0, $p = 0.006$). A series of pleiotropy-robust and outlier detection methods
110 showed that pleiotropy did not bias our findings.

111

112 **Conclusion**

113 We found limited evidence for a role of cholesterol-lowering in OC and OPC risk,
114 suggesting previous observational results may have been confounded. There was some
115 evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering
116 variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the
117 mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol
118 lowering effects, but further replication of this finding is required.

119 **Author summary**

120 **Why was this study done?**

121 • To determine if genetically-proxied cholesterol-lowering drugs (such as statins which
122 target HMGCR) reduce oral and oropharyngeal cancer risk.

123 • To determine if genetically-proxied circulating lipid traits (e.g. low-density
124 lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

125

126 **What did the researchers do and find?**

127 • There was little evidence that genetically-proxied inhibition of HMGCR (target of
128 statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences
129 oral or oropharyngeal cancer risk.

130 • There was little evidence of an effect of circulating lipid traits on oral or
131 oropharyngeal cancer risk.

132 • There was some evidence that genetically-proxied inhibition of PCSK9 increases,
133 while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk .

134

135 **What do these findings mean?**

136 • These findings suggest that the results of previous observational studies examining
137 the effect of statins on oral and oropharyngeal risk may have been confounded.

138 • Given we found little evidence of an effect of other cholesterol lowering therapies,
139 the mechanism of action of PCSK9 may be independent of cholesterol-lowering.
140 Further replication of this finding in other head and neck cancer datasets is required.

141

142

143 **Introduction**

144

145 Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral
146 cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over
147 550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements
148 in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence
149 rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and
150 chemotherapy which can result in significant morbidity [5]. Established risk factors include
151 smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with
152 oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases
153 (versus <5% of OC cases) are HPV driven and often present in younger populations, oral and
154 oropharyngeal tumours are considered distinct disease entities, with different risk factor
155 profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation
156 of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel
157 strategies for prevention of HNSCC are required, in particular for those at high risk and one
158 approach is to identify novel risk factors which can be easily modified, for example by
159 repurposing existing drugs [9].

160

161 Statins are one of the most commonly prescribed medications worldwide. They are
162 prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-
163 C), with proven preventative and therapeutic effects in cardiovascular disease and a good
164 safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase
165 (HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway,
166 responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

167 drugs that target cholesterol metabolism via different mechanisms include ezetimibe
168 (targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase
169 subtilisin/kexin type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents
170 act by reducing the intestinal absorption of cholesterol or by enhancing uptake of LDL-C
171 through increased cellular membrane expression of the LDL-receptor (LDLR), respectively.
172 Conversely, cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels
173 of high-density lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse
174 cholesterol transport [13].

175

176 Cholesterol is vital for a variety of key cellular functions, including membrane
177 integrity, signalling, protein synthesis and cell cycle progression. Therefore, modulation of
178 cholesterol synthesis has the potential to influence several hallmarks of tumourigenesis
179 including cell migration and proliferation [14]. In an experimental study, mice given oral
180 daily doses of simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative
181 hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study
182 was designed to mimic a clinical scenario where patients who present with a tumour may
183 have been taking the medication prior to tumour initiation [15], and suggested that
184 simvastatin antagonises tumour metabolic reprogramming, another important hallmark of
185 cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development
186 comes largely from the fact that lipids are themselves major cell membrane components
187 essential for cell division and maintaining tissue integrity. Changes in lipid levels have been
188 reported associated with tumour development [16, 17].

189

190 However, the evidence that cholesterol-lowering drugs may reduce the risk of head
191 and neck cancer is limited. Some observational studies report an inverse association of
192 taking statins with both head and neck cancer risk and survival [14, 18], but others indicate
193 little evidence of any effect [19]. Observational studies are not randomised and are
194 susceptible to reverse causality and/or confounding [19]. Mendelian randomization (MR) is
195 an approach that uses germline genetic proxies (referred to as instruments) to help appraise
196 causal effects of potentially modifiable extrinsic exposures or intrinsic traits with disease
197 [20-22]. It has also been used to estimate therapeutic potential by investigating genetic
198 variation at drug targets [23]. Numerous single nucleotide polymorphisms (SNPs) are
199 associated with lower levels of circulating LDL-C [24, 25] and inheriting an LDL-C lowering
200 allele has been proposed to be analogous to being assigned life-long treatment with a
201 cholesterol lowering drug [26]. In this way, germline genetic variants may serve as proxies
202 for exposure to potential pharmacological agents which are less likely than observational
203 measures to be subject to reverse causation or confounding. Genetic proxies can therefore
204 be used to predict both the likely beneficial and adverse effects of long-term modulation of
205 the drug targets on disease.

206

207 MR has previously demonstrated the protective effect of cholesterol-lowering drugs
208 on cardiovascular disease risk [27] , but also that inhibition of HMGCR and PCSK9 may have
209 an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have
210 shown that genetically-proxied inhibition of HMGCR may be protective against overall
211 cancer [29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the
212 causal nature and mechanistic basis of the relationship between cholesterol-lowering and

213 risk of oral and oropharyngeal cancer by investigating germline variation in *HMGCR*,
214 *NPC1L1*, *CETP*, *PCSK9* and *LDLR*, and other related lipid traits such as circulating LDL-C.

215

216 **Methods**

217

218 **Identifying cholesterol-lowering genetic instruments.** For the primary analysis, SNPs in
219 *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* were used to proxy the effect of lipid-lowering
220 therapies and to estimate the downstream effect of manipulating these targets on OC and
221 OPC risk. SNPs were identified within 100 kb on either side of the target gene (*HMGCR*,
222 *NPC1L1*, *CETP*, *PCSK9* and *LDLR*) that were associated with LDL-C levels. Variants were
223 robustly associated with LDL-C in a meta-analysis of genome-wide association studies
224 (GWAS) involving 188,578 individuals primarily (96%) of European ancestry in the Global
225 Lipids Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r^2) was evaluated to
226 check the overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were
227 permitted to be in weak LD ($r^2 < 0.2$) with each other, to increase the proportion of variance
228 explained in each respective drug target therefore maximising instrument strength. Multiple
229 papers have used these genetic instruments at this threshold, to demonstrate causal effects
230 in cardiovascular disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary
231 analyses, SNPs were used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total
232 cholesterol, apolipoprotein A and B. Betas represented the change in lipid trait levels per
233 copy of the effect allele. These SNPs were already independently ($r^2 < 0.001$) associated with
234 the respective traits in large GWAS which have been described previously [25, 33].

235

236 **Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.**

237 We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC
238 using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part
239 of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The
240 study population included participants from Europe (45.3%), North America (43.9%) and
241 South America (10.8%). Cancer cases comprised the following the International
242 Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,
243 C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),
244 overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code
245 (other). A total of 954 individuals with cancers of hypopharynx, unknown code or
246 overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was
247 genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray
248 custom designed for cancer studies by the OncoArray Consortium [35]. In GAME-ON, all
249 SNPs with a call rate of <95% were excluded. Given the ethnic heterogeneity of the study
250 population, the dataset was divided by geographical region and SNPs within each region
251 that showed deviation from Hardy-Weinberg Equilibrium (HWE) in controls ($p = <1 \times 10^{-7}$)
252 were excluded. Principal component analysis (PCA) was performed using approximately
253 10,000 common markers in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139
254 population outliers were removed. Full details of the included studies, as well as the
255 genotyping and imputation performed, have been described previously [34, 36].

256

257 **Two-sample Mendelian randomization.** Two-sample MR was conducted using the
258 “TwoSampleMR” package in R (version 3.5.3), by integrating SNP associations for
259 cholesterol-lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For

260 those SNPs instrumenting LDL-C lowering, we first extracted summary statistics for the
261 associations with OC and OPC from GAME-ON. We next performed harmonisation of the
262 direction of effects between the cholesterol-lowering exposures and outcome (OC or OPC)
263 where, for each variant, the allele designated the 'exposure allele' was associated with
264 lower LDL-C levels and palindromic SNPs were aligned when MAFs were <0.3 or were
265 otherwise excluded. In our primary analysis, four palindromic SNPs, one in *HMGCR*
266 (rs2006760), the other in *PCSK9* (rs2149041) and two in *CETP* (rs5880, rs9929488) were
267 removed. In the secondary analysis with other lipid traits, 11 palindromic SNPs (rs1936800,
268 rs2288912, rs7112577, rs964184, rs150617279, rs1883711, rs4722043, rs2156552,
269 rs2954029, rs581080, rs7534572) were removed.

270

271 Individual effect-estimates for each SNP were calculated using the Wald ratio, by
272 dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were
273 then combined into multi-allelic instruments using the random-effects inverse-variance
274 weighted (IVW) meta-analysis method, for each of the genes *HMGCR*, *NPC1L1*, *CETP*, *PCSK9*
275 and *LDLR*. This meta-analysis was undertaken to increase the proportion of variance in drug
276 targets and LDL-C lowering explained by each instrument, and thus improve statistical
277 power and the precision of our estimates [37]. The analysis produced an estimate of the
278 effect of the risk factor on OC and OPC risk. As the instruments for *HMGCR*, *NPC1L1*, *CETP*,
279 *PCSK9* and *LDLR* were in weak LD ($r^2 < 0.2$), we accounted for this correlation between SNPs
280 in the primary analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the
281 1000 Genomes Project and variant rs numbers based on dbSNP. Correlation matrices were
282 inserted as an MRInput object [31], resulting in MR methods which altered the weightings
283 for correlated SNPs [38-40]. For circulating lipid traits, a more stringent $r^2 < 0.001$ was

284 already applied in the initial GWAS [25], so we did not account further for correlation in the
285 secondary analysis. We computed odds ratios (OR) which represent the change in odds of
286 oral and oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of the
287 drug target, equivalent to a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1
288 mmol/L decrease by dividing the LDL-C lowering effect (beta) and standard error (se)
289 measured in mg/dL by 38.7 [30]. The betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*,
290 *PCSK9* and *LDLR* SNPs were also converted to reflect the cholesterol-lowering effect, given
291 the “TwoSampleMR” package preference to automatically change these into a positive
292 direction of effect (i.e. lipid increasing). The correct direction of effect was checked using a
293 positive control of coronary heart disease from the CARDIoGRAM GWAS data [41]. MR was
294 also used to examine the effect of circulating levels of LDL-C, HDL-C, total triglyceride, total
295 cholesterol, apolipoprotein A and B levels directly with OC and OPC cancer risk. The ORs in
296 this analysis represent the change in odds of oral or oropharyngeal squamous cell
297 carcinoma, per SD unit increase in lipid trait.

298

299 The IVW method can provide an unbiased effect estimate in the absence of
300 horizontal pleiotropy or when horizontal pleiotropy is balanced [42]. We therefore
301 performed sensitivity analyses to evaluate the potential for unbalanced horizontal
302 pleiotropy, where genetic variants influence two or more traits through independent
303 biological pathways. To ensure the genetic instrument was associated with the instrument it
304 was proxying, estimates of the proportion of variance in each risk factor explained by the
305 instrument (R^2) and F-statistics were generated. An F-statistic of <10 is indicative of a weak
306 instrument which may be subject to weak instrument bias. To account for directional
307 pleiotropy, we compared the IVW results with three MR sensitivity analyses, which each

308 make different assumptions: MR Egger [43], weighted median [44] and weighted mode [45].
309 While these three methods are best used when genetic instruments consist of a large
310 numbers of independent SNPs, since r^2 values between SNPs in our instruments were low
311 ($r^2 < 0.2$), we a-priori decided to include them, with a further sensitivity analysis to account
312 for correlation in the MR Egger analysis. The weighted median stipulates that at least 50% of
313 the weight in the analysis stems from variants that are valid instruments [44], while the
314 weighted mode requires that the largest subset of instruments which identify the same
315 causal effect to be valid instruments [45]. MR-Egger can provide unbiased estimates even
316 when all SNPs in an instrument violate the exclusion restriction assumption (i.e. affect the
317 outcome by means other than via the risk factor of interest). However, there must be
318 negligible measurement error (NOME) [46] in the genetic instrument and the InSIDE
319 (Instrument Strength Independent of Direct Effect) assumption must be satisfied [43].
320 Where there was evidence of violation of the NOME assumption, this was assessed using
321 the I^2 statistic and MR-Egger was performed with simulation extrapolation (SIMEX)
322 correction [46]. To further assess the robustness of findings, we examined evidence of
323 heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may
324 indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [47]. Scatter
325 and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO
326 (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and
327 correct for potential outliers (where Q-statistic $p < 0.05$) [48].

328

329 **Stratification by cancer subsite.** Given the difference in established aetiology (i.e. smoking,
330 alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification
331 by cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS
332 summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC
333 cases and the 6,585 common controls in the GAME-ON GWAS [34].

334

335 **Replication in UK Biobank.** UK Biobank data was used as a replication dataset for primary
336 analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls,
337 with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large
338 population-based cohort study that recruited over 500,000 men and women aged between
339 37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval
340 from the National Health Service North West Centre for Research Ethics Committee
341 (reference: 11/NW/0382). Details of genotyping quality control, phasing and imputation are
342 described elsewhere [49]. Participant records are linked to cancer registry data and HNSCC
343 was grouped using the same ICD-codes as described above. Squamous cell carcinoma cases
344 were identified using histology codes 8070 – 8078. UK Biobank GWAS analyses were
345 adjusted for sex and genotyping array and performed in BOLT-LMM, a mixed model that
346 accounts for population stratification and relatedness [50, 51]. Primary MR analyses as
347 described above in GAME-ON were repeated in UK Biobank data.

348

349 **Meta-analysis of results.** We performed both fixed-effects and random-effects meta-
350 analysis of the MR estimates in GAME-ON and UK Biobank using the R package ‘meta’.
351 However, we focus more on the fixed-effects estimates since we assume that the causal

352 effect is constant between the studies [52]. Heterogeneity between study populations was
 353 assessed using I^2 statistic [53].

354

355 Results

356

357 **Primary analysis in GAME-ON.** In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909,
 358 rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs
 359 in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1
 360 inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775,
 361 rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409,
 362 rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied
 363 cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition).
 364 Further details of these SNP effects are given in **Table 1**.

365

366 **Table 1.** Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*,
 367 *PCSK9* and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

368

Target	SNP	Pathway	EA	OA	EAF	Beta	se	P-value
<i>HMGCR</i>	rs12916	LDL-C	T	C	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	T	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	A	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	A	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	A	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	C	G	0.81	-0.04407	0.006	1.67E-13
<i>NPC1L1</i>	rs217386	LDL-C	A	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	A	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	T	C	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	C	T	0.90	-0.02363	0.005	1.52E-06

	rs2300414	LDL-C	G	A	0.93	-0.02828	0.006	5.45E-06
<i>CETP</i>	rs3764261	LDL-C	A	C	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	A	C	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	A	0.73	-0.03698	0.004	7.97E-21
	rs9929488*	LDL-C	G	C	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	A	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	T	C	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	A	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	C	0.94	-0.03979	0.008	1.59E-06
<i>PCSK9</i>	rs11206510	LDL-C	C	T	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	A	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	C	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	A	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	T	C	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	C	T	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	A	0.19	-0.05292	0.002	6.16E-21
<i>LDLR</i>	rs6511720	LDL-C	T	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	T	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	C	T	0.56	-0.04465	0.003	3.04E-48

369

370 EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-

371 effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed

372 Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L

373 to mg/dL, multiply by 38.7.

374

375 There was limited evidence of an effect of genetically-proxied inhibition of HMGCR

376 and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95%

377 CI 0.4, 2.7, p= 0.99), respectively. (**Table 2** and **S1 Fig**). A similar result was found for

378 genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3;

379 95%CI 0.6, 2.6, p= 0.49) (**Table 2** and **S1 Fig**). However, higher risk of combined OC and OPC

380 was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7

381 mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; **Table 2** and **Fig 1**). This is in

382 contrast to the reduction in odds seen in relation to cardiovascular disease using the same

383 instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p < 1 x10⁻⁰³; **Fig 2**) in 60,801 cases and 123,504

384 control subjects enrolled in the CARDIoGRAM consortia studies [41]. There was also some
385 evidence that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to
386 a 1 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI
387 0.4, 1.0, $p = 0.05$; **Table 2, Fig 1**).

388

389 **Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR***
390 **variants on the oral and oropharyngeal cancer subsites in GAME-ON.** Effect estimates on
391 oral and oropharyngeal cancer are reported on the log odds scale.

392

393 **Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR***
394 **single nucleotide polymorphisms on coronary heart disease and combined oral/**
395 **oropharyngeal cancer in GAME-ON.** Effect estimates on oral and oropharyngeal cancer are
396 reported on the log odds scale.

397 **Table 2.** Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and
 398 oropharyngeal cancer including sensitivity analyses in GAME-ON
 399

	Outcome	Exposure/ Outcome dataset	Outcome N	Number of SNPs	IVW		Weighted median		Weighted mode		MR-Egger	
					OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
HMGCR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

PCSK9	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	3.49 (1.58, 7.68)	2.00 E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
LDLR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
	Oral cancer	GAME-ON/ GLGC	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51

400

401 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value.

402

403 OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent

404 to a 1 mmol/L decrease in LDL-C.

405 **Stratification by cancer subsite in GAME-ON.** When stratified by subsite, the
406 adverse effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6,
407 7.7, $p= 2 \times 10^{-03}$), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, $p= 0.11$)
408 (**Table 2 & Fig 1**). The effects appeared stronger in OPC versus OC, but with overlapping
409 confidence intervals. LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI
410 0.3, 0.9, $p= 0.01$), but there was little evidence of an association with OPC (OR IVW 0.9;
411 95%CI 0.5, 1.5, $p= 0.69$) (**Table 2 and Fig 1**). For both PCSK9 and LDLR associations, the
412 direction of effect was generally consistent across the four MR methods tested (**Table 2**).

413

414 **Secondary analysis in GAME-ON.** SNPs were also used to proxy circulating levels of LDL-C
415 (77 SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54
416 SNPs), total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs)
417 (**S1 Table**). There was limited evidence of an effect of any of these other lipid traits on either
418 OC or OPC (**Table 3 and S2 Fig**).

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438 **Table 3.** Mendelian randomization results of circulating lipid traits with risk of oral and
 439 oropharyngeal cancer in GAME-ON

Target	N SNPs	Outcome	IVW OR (95% CI)	P-value
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

440

441 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

442 IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma
 443 per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,
 444 Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total
 445 cholesterol = 41.8 mg/dL).

446 **Sensitivity analyses.** IVW, MR Egger, weighted median, simple and weighted mode were
447 carried out, in addition to IVW analysis accounting for LD structure (**S2.1-2.5 Tables**). The
448 results adjusting for SNP correlation followed the same pattern as the main results (**S3**
449 **Table**). There was limited evidence of weak instrument bias being present (F-statistic >10)
450 and the proportion of variance in the phenotype (R^2) explained by the genetic instruments
451 ranged from 0.1 to 6% (**S4 Table**). In both primary and secondary analyses there was limited
452 evidence of heterogeneity in the SNP effect estimates for IVW and MR Egger regression,
453 except for in HDL-C (Q IVW 115.7, $p=0.01$; Q MR Egger 115.6, $p=0.01$) (**S5 and S6 Tables**).

454

455 MR Egger intercepts also indicated limited evidence of directional pleiotropy (**S7 and**
456 **S8 Tables**). For the primary analysis there were no clear outliers in both scatter and leave-
457 one-out plots (**Fig 3 and S3-6 Figs**) and MR-PRESSO detected no individual outliers (**S9**
458 **Table**). Where there was evidence of violation of the NOME assumption for the HMGCR,
459 NPC1L1 and CETP instruments (i.e. I^2 statistic <0.90) (**S10 Table**), MR-Egger was performed
460 with SIMEX correction and effects were still consistent with the null (**S11 Table**).

461

462 **Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on**
463 **combined oral/ oropharyngeal cancer in GAME-ON.**

464

465 **Replication in UK Biobank and meta-analysis of results.** Primary MR analyses as described
466 above were replicated in UK Biobank, showing limited evidence of an effect of genetically-
467 proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (**S12**
468 **Table**). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results,
469 there was a consistently strong effect of genetically-proxied PCSK9 inhibition on combined

470 OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies ($I^2= 22%$)
471 and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC
472 (OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate
473 heterogeneity between studies ($I^2= 41%$) (**Fig 4**). Conversely, the protective effect for LDLR
474 on OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5,
475 1.0), with good concordance between studies ($I^2= 0%$) (**Fig 5** and **S7 Fig**). However, the
476 protective effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9)
477 was not replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of
478 heterogeneity between the studies ($I^2= 66%$).

479

480 **Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
481 **lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.**

482

483 **Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
484 **lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.**

485

486 **Discussion**

487

488 We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This
489 included the absence of a protective effect of genetically-proxied inhibition of HMGCR,
490 suggesting previous observational studies investigating the relationship between statins and
491 head and neck cancer risk may be subject to residual confounding or bias. However, we did
492 observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar
493 magnitude to the protective effect seen in relation to cardiovascular disease using the same

494 genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n= 6,034 OC
495 and OPC cases and n= 6,585 controls) and UK Biobank datasets (n= 839 OC and OPC cases
496 and n= 372,016 controls). We also found some evidence for a protective effect of
497 cholesterol-lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis
498 for HMGCR, NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure ($r^2 < 0.2$) followed
499 the same pattern as the main results (**S3 Table**).

500

501 **Association between PCSK9, LDLR and cancer risk.** Despite the lack of consistent evidence
502 for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both
503 PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the
504 development of OC or OPC via other mechanisms. The effects identified in the present study
505 are directionally consistent with a recent MR analysis of 1,615 combined head and neck
506 cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied
507 by PCSK9 and LDLR was associated with a reduction (OR 0.7 95%CI 0.4, 1.4, $p = 0.35$) and
508 increase in odds (OR 1.6 95%CI 1.0, 2.4, $p = 0.05$) of head and neck cancer, respectively [29].
509 The opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering
510 is unlikely to be the main mechanism of action. However, this previous analysis is limited by
511 the relatively small number of cases and heterogeneity of head and neck cancer subtypes,
512 with no selection for the histological subtype of squamous cell carcinoma. In the present
513 study, we focused specifically on oral and oropharyngeal subtypes of HNSCC.

514

515 Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential
516 pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an
517 increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in

518 LDL-C) [28]. However, a recent genome-wide association study (PheWAS) did not
519 find *PCSK9* or *LDLR* to be correlated with any non-lipid-related phenotypes, including
520 diabetes [54]. There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in
521 both cell proliferation and apoptosis. The gene was initially designated as NARC1 (neural
522 apoptosis-regulated convertase 1), involved in apoptosis of cerebellar neurons [55] and
523 *PCSK9* has since been found to be upregulated in some cancers [56, 57].

524

525 One suggested mechanism for a link with cancer progression is that the increased
526 expression of *PCSK9* prevents LDL-receptor (*LDLR*) recycling, leading to
527 hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour
528 [55]. Our study suggests the opposite, that genetically-proxied inhibition of *PCSK9* results in
529 an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in
530 fact be pro-tumourigenic, providing a favourable environment for a developing tumour cell,
531 maintaining membrane integrity and promoting cell division. Therapies such as statins,
532 ezetimibe, and *PCSK9* inhibitors may all lower LDL-C level through the upregulation of LDL-
533 receptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are
534 often context dependent and perhaps only the expression of *PCSK9* and *LDLR* is relevant in
535 head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from
536 HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as
537 enhancing reverse cholesterol transport [58]. Unlike statins, CETP inhibitors do not appear
538 to increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell
539 cholesterol accumulation with use of other cholesterol-lowering drugs [59]. Therefore, the
540 absence of effect when proxying *CETP* inhibition in this study, supports the possible
541 mechanism of LDL-C uptake via the LDL-receptor in OC or OPC.

542

543 While both *PCSK9* [60] and *LDLR* [61] are expressed in head and neck tumours, this was not
544 evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not
545 available in expression datasets [62]. Recent studies have associated elevated *PCSK9* with
546 alcohol use disorder, including the interesting possibility of using anti-*PCSK9* monoclonal
547 antibodies for the treatment of alcoholic liver disease [63, 64]. Given that alcohol is a well-
548 known risk factor for HNSCC, this pleiotropy could have partially explained the effect seen in
549 our study, however we proxied the inhibition of *PCSK9* and so would have expected to see a
550 protective effect of this gene in HNSCC cases who may have been heavy alcohol drinkers.
551 Further investigation is required to untangle the relationship between *PCSK9*, alcohol and
552 head and neck cancer.

553

554 **Comparison with previous studies.** It is believed that statins could play a potential role in
555 cancer chemoprevention which may reduce the risk of some site-specific cancers such as
556 prostate [65] and ovarian [30], but not all. Some of these studies have reported cancer risk
557 reductions by as much as 50 – 65% [66-68]. However, meta-analyses and clinical trials have
558 contradicted these findings [69, 70]. In addition to confounding, immortal time bias likely
559 inflated observational results because, to be classified as a long-term statin user
560 necessitates that users survived without cancer over a long period [19, 71]. Dickerman et al.
561 used electronic records from 733,804 adults with 10-year follow-up to emulate a trial
562 design. To achieve this a pre-specified protocol was set, including eligibility criteria and
563 checks were made to ensure effect estimates for statins on cancer were comparable
564 between the large observational dataset and trial. The authors found little indication that
565 statin therapy influences cancer incidence, which was consistent with the analyses of

566 randomised trials (with a 10-year cancer-free survival difference of -0.3% 95%CI -1.5% ,
567 0.5%) [19]. Nonetheless, recent MR studies [29, 30] have identified an association between
568 variants in *HMGCR* with cancer risk, but not alternative cholesterol-lowering treatments or
569 genetically-predicted LDL-C, suggesting that statins may reduce cancer risk through a
570 cholesterol independent pathway. A recent case-control study of over 11,000 participants
571 found an inverse association between statin use and the occurrence of HNSCC (OR 0.86,
572 95%CI 0.77, 0.95, $p = <0.01$, of prior statin exposure for cases compared to propensity
573 score-matched controls) [18]. However, a wider systematic review found that the evidence
574 for the role of statins in the prevention of HNSCC was limited [72]. As HNSCC incidence is a
575 rare outcome, randomised controls trials are not feasible, so we must be cautious
576 interpreting the available observational findings given the potential for bias and
577 confounding as discussed previously.

578

579 In contrast to previous MR studies assessing overall cancer risk [29] and ovarian
580 specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using
581 genetic instruments for *HMGCR* (statins). There was also limited evidence for a causal effect
582 of *NPC1L1* (ezetimibe), *CETP* (CETP inhibitors) as well as a number of other circulating lipid
583 traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with
584 *PCSK9* and *LDLR* are via LDL-C lowering or another less well-established pathway [73, 74],
585 such as receptor regulation for viral entry, synthesis of sex hormones and resultant
586 dysregulated metabolism [75-77].

587

588 **Strengths and limitations of this study.** Protective associations between cholesterol-
589 lowering therapies such as statins and head and neck cancer risk seen in previous

590 observational studies could be a result of reverse causation, immortal time bias, lack of
591 randomisation or confounding by socioeconomic status, smoking or HPV infection, for
592 example. Our study applied MR in an attempt to overcome these issues, using the largest
593 number of SNPs identified from the latest GWAS for both cholesterol-lowering and head
594 and neck cancer that could be identified in the literature [25, 34]. A series of pleiotropy-
595 robust MR methods and outlier detection were applied to rigorously explore the possibility
596 that findings were not biased as a result of pleiotropy. However, there was no HPV data
597 available in these summary results to enable more detailed stratified analysis of OPC. We
598 did replicate findings for PCSK9 and LDLR, but the number of cases are low. Finally, most
599 participants in the GAME-ON network [34] were of European or North American descent,
600 with only around 11% from South America, and participants included in the UK Biobank
601 analysis were exclusively of European descent, so more work is required to determine if our
602 results translate to other ancestry groups.

603

604 In conclusion, our MR analyses provided little evidence for a role of cholesterol
605 lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and
606 cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given
607 the lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may
608 be common to all tumours, regardless of the activated molecular pathway, could help
609 simplify a preventative or therapeutic approach [78]. Replication of our findings in other
610 head and neck cancer datasets and use of individual-level follow-up data with HPV status
611 could provide further insight into the effect of these genetic instruments on risk, treatment
612 outcomes and survival in head and neck cancer. With more evidence, future randomised

613 control trials could focus on treating high risk OC or OPC groups, such as those with severe
614 dysplasia or who are HPV-16 E6 positive, with cholesterol-lowering therapies.

615

616 **Data availability statement**

617

618 Summary-level analysis was conducted using publicly available GWAS data [25, 33].

619 Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray:

620 Oral and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK

621 Biobank (<https://www.ukbiobank.ac.uk/>) data is available to researchers through

622 application.

623

624 **Code availability statement**

625

626 Two-sample MR analyses were conducted using the “TwoSampleMR” package in R

627 (version 3.5.3). A copy of the code used in this analysis will be made available at:

628 https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer

629

630 **Acknowledgements**

631

632 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and

633 is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

634 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].

635 For the purpose of open access, the author has applied a CC BY public copyright licence to

636 any Author Accepted Manuscript version arising from this submission. UK Biobank approval
637 was given for this project (ID 40644 “Investigating aetiology, associations and causality in
638 diseases of the head and neck”) and UK Biobank GWAS data was also accessed under the
639 application (ID 15825 “MR-Base: an online resource for Mendelian randomization using
640 summary data”- Dr. Philip Haycock). R.C.R. is a de Pass VC research fellow at the University
641 of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award,
642 which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund
643 (GCRF), the Government Department of Business, Energy and Industrial strategy, the British
644 Heart Foundation and Diabetes UK (SBF004\1079). R.M.M. was supported by a Cancer
645 Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology
646 Programme) and is part of the Medical Research Council Integrative Epidemiology Unit at
647 the University of Bristol supported by the Medical Research Council (MC_UU_12013/1,
648 MC_UU_12013/2, and MC_UU_12013/3) and the University of Bristol. JY is supported by a
649 Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). R.M.M.
650 and A.R.N. are supported by the National Institute for Health Research (NIHR) Bristol
651 Biomedical Research Centre which is funded by the National Institute for Health Research
652 (NIHR) and is a partnership between University Hospitals Bristol and Weston NHS
653 Foundation Trust and the University of Bristol. This publication presents data from the Head
654 and Neck 5000 study. The study was a component of independent research funded by the
655 NIHR under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The
656 views expressed in this publication are those of the author(s) and not necessarily those of
657 the NHS, the NIHR or the Department of Health. Core funding was also provided through
658 awards from Above and Beyond, University Hospitals Bristol Research Capability Funding
659 and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was

660 supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology
661 Programme (grant number: C18281/A19169). B.D. and the University of Pittsburgh head and
662 neck cancer case-control study are supported by US National Institutes of Health (NIH)
663 grants: P50 CA097190, P30 CA047904 and R01 DE025712. The genotyping of the HNSCC
664 cases and controls was performed at the Center for Inherited Disease Research (CIDR) and
665 funded by the US National Institute of Dental and Craniofacial Research (NIDCR;
666 1X01HG007780-0). The University of North Caroline (UNC) CHANCE study was supported in
667 part by the National Cancer Institute (R01-CA90731). E.E.V and D.L are supported by
668 Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund
669 (WCRF UK), as part of the World Cancer Research Fund International grant programme
670 (IIG_2019_2009). E.H.T and P.S. were supported by the GENCAPO/FAPESP grant (10/51168-
671 0).

672

673 **Competing Interests**

674 The authors declare no conflicts of interest. The funders had no role in the design of
675 the study; the collection, analysis, and interpretation of the data; the writing of the
676 manuscript; and the decision to submit the manuscript for publication. The authors alone
677 are responsible for the views expressed in this article.

678

679 **References**

680

- 681 1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral
682 Oncol. 2009;45(4-5):309-16.
- 683 2. Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender
684 and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral
685 tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-
686 based analysis. Oncology. 2011;81(1):12-20.
- 687 3. Cancer Research UK (CRUK). Head and neck cancer statistics 2019 [cited 2019
688 11/04/2019]. Available from: [https://www.cancerresearchuk.org/health-
689 professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-
690 Two](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two).
- 691 4. Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom
692 National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90.
- 693 5. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and
694 psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol
695 Head Neck Surg. 1999;120(3):427-36.
- 696 6. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck
697 squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003.
- 698 7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human
699 papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.
700 2010;363(1):24-35.

- 701 8. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal
702 cancer: the basics to know in clinical practice. *Acta Otorhinolaryngol Ital.* 2014;34(5):299-
703 309.
- 704 9. Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in
705 cancer. *Pharmacol Res.* 2017;124:74-91.
- 706 10. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. *Ther Adv Drug Saf.*
707 2012;3(3):133-44.
- 708 11. Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The
709 'top 100' drugs and classes in England: an updated 'starter formulary' for trainee
710 prescribers. *British Journal of Clinical Pharmacology.* 2018;84(11):2562-71.
- 711 12. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA
712 reductase. *Science.* 2001;292(5519):1160-4.
- 713 13. Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.
714 Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein
715 Levels and Cardiovascular Risk. *JAMA.* 2017;318(10):947-56.
- 716 14. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related
717 Mortality. *New Engl J Med.* 2012;367(19):1792-802.
- 718 15. Mehibel M, Ortiz-Martinez F, Voelken N, Boyers A, Chadwick A, Telfer BA, et al.
719 Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting
720 monocarboxylate transporters. *Sci Rep.* 2018;8(1):16804.

- 721 16. Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum
722 lipid levels and the risk of oral cancer. *Indian J Med Paediatr Oncol.* 2011;32(1):34-7.
- 723 17. Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in
724 patients with oral cancer and oral precancerous conditions. *Dent Res J (Isfahan).*
725 2014;11(3):345-50.
- 726 18. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and
727 head and neck cancer: Population-based case-control study in Han population. *Head Neck-J*
728 *Sci Spec.* 2019;41(5):1193-8.
- 729 19. Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws
730 in observational analyses: an application to statins and cancer. *Nat Med.* 2019;25(10):1601-
731 6.
- 732 20. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
733 contribute to understanding environmental determinants of disease? *Int J Epidemiol.*
734 2003;32(1):1-22.
- 735 21. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
736 inference in epidemiological studies. *Hum Mol Genet.* 2014;23(R1):R89-98.
- 737 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
738 guide, glossary, and checklist for clinicians. *BMJ.* 2018;362:k601.
- 739 23. Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel
740 approach for the prediction of adverse drug events and drug repurposing opportunities. *Int J*
741 *Epidemiol.* 2017;46(6):2078-89.

- 742 24. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
743 Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*.
744 2010;466(7307):707-13.
- 745 25. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.
746 Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45(11):1274-+.
- 747 26. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-
748 density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,
749 epidemiologic, and clinical studies. A consensus statement from the European
750 Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38(32):2459-72.
- 751 27. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
752 allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
753 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian
754 randomization study. *J Am Coll Cardiol*. 2015;65(15):1552-61.
- 755 28. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.
756 Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. *N Engl J*
757 *Med*. 2016;375(22):2144-53.
- 758 29. Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the
759 effect of statins on cancer risk using genetic variants: a Mendelian randomization study in
760 UK Biobank. *medRxiv*. 2020:2020.02.28.20028902.

- 761 30. Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association
762 Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian
763 Cancer. *JAMA*. 2020;323(7):646-55.
- 764 31. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
765 specific haplotype structure and linking correlated alleles of possible functional variants.
766 *Bioinformatics*. 2015;31(21):3555-7.
- 767 32. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
768 Randomization Study of ACLY and Cardiovascular Disease. *N Engl J Med*. 2019;380(11):1033-
769 42.
- 770 33. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
771 study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
772 *Nat Commun*. 2016;7:11122.
- 773 34. Lesueur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide
774 association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
775 *Nat Genet*. 2016;48(12):1544-50.
- 776 35. Consortium O. Consortium launches genotyping effort. *Cancer Discov*.
777 2013;3(12):1321-2.
- 778 36. Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing
779 the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal
780 cancer using Mendelian randomization. *Int J Cancer*. 2018;143(5):1029-36.

- 781 37. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian
782 randomization studies. *Int J Epidemiol.* 2013;42(5):1497-501.
- 783 38. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing
784 Mendelian randomization analyses using summarized data. *Int J Epidemiol.*
785 2017;46(6):1734-9.
- 786 39. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data
787 in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur*
788 *J Epidemiol.* 2015;30(7):543-52.
- 789 40. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
790 instrumental variables in Mendelian randomization: comparison of allele score and
791 summarized data methods. *Stat Med.* 2016;35(11):1880-906.
- 792 41. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
793 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
794 *Nat Genet.* 2015;47(10):1121-30.
- 795 42. Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in
796 Mendelian randomization studies. *Hum Mol Genet.* 2018;27(R2):R195-R208.
- 797 43. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
798 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.*
799 2015;44(2):512-25.

- 800 44. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian
801 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet*
802 *Epidemiol.* 2016;40(4):304-14.
- 803 45. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
804 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* 2017;46(6):1985-
805 98.
- 806 46. Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing
807 the suitability of summary data for two-sample Mendelian randomization analyses using
808 MR-Egger regression: the role of the I-2 statistic. *Int J Epidemiol.* 2016;45(6):1961-74.
- 809 47. Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving
810 the visualization, interpretation and analysis of two-sample summary data Mendelian
811 randomization via the Radial plot and Radial regression. *Int J Epidemiol.* 2018;47(4):1264-78.
- 812 48. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread
813 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
814 between complex traits and diseases. *Nat Genet.* 2018;50(8):1196.
- 815 49. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide
816 genetic data on ~500,000 UK Biobank participants. *bioRxiv.* 2017:166298.
- 817 50. Mitchell R, Hemani, G, Dudding, T, Corbin, L, Harrison, S, Paternoster, L. UK Biobank
818 Genetic Data: MRC-IEU Quality Control, version 2.
819 <https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v>. 2019.

- 820 51. Mitchell R, Elsworth BL, Mitchell R, Raistrick CA, Paternoster L, Hemani G, Gaunt TR
821 MRC IEU UK Biobank GWAS pipeline version 2.
822 <https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaekeigi>. 2019.
- 823 52. Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.
- 824 53. Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-
825 60.
- 826 54. Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-
827 wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom
828 Med. 2019;4:3.
- 829 55. Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology
830 beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.
- 831 56. Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network
832 analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.
833 2017;13(8):938.
- 834 57. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar
835 NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.
836 Proteomics Clin Appl. 2013;7(5-6):355-66.
- 837 58. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL
838 receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent
839 mechanism. Atherosclerosis. 2014;235(2):449-62.

- 840 59. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. *Atherosclerosis*.
841 2018;278:143-6.
- 842 60. The Human Protein Atlas. PCSK9 2020 [Available from:
843 <https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology>.
- 844 61. The Human Protein Atlas. LDLR 2020 [Available from:
845 <https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology>.
- 846 62. The Human Protein Atlas. LDLR Tissue 2020 [Available from:
847 <https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue>.
- 848 63. Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9
849 inhibition as a novel therapeutic target for alcoholic liver disease. *Scientific Reports*.
850 2019;9(1):17167.
- 851 64. Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in
852 Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. *Alcoholism: Clinical and*
853 *Experimental Research*. 2019;43(6):1163-9.
- 854 65. Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason
855 score-specific prostate cancer: A hospital-based cohort study. *Cancer Medicine*.
856 2019;8(17):7399-407.
- 857 66. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and
858 the risk of colorectal cancer. *N Engl J Med*. 2005;352(21):2184-92.
- 859 67. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer
860 in humans: a large case-control study of US veterans. *Chest*. 2007;131(5):1282-8.

- 861 68. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins
862 and prostate cancer risk: a case-control study. *Am J Epidemiol*. 2005;162(4):318-25.
- 863 69. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,
864 Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of
865 individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One*.
866 2012;7(1):e29849.
- 867 70. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a
868 meta-analysis. *JAMA*. 2006;295(1):74-80.
- 869 71. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial
870 prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin*
871 *Epidemiol*. 2016;79:70-5.
- 872 72. Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of
873 metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic
874 review. *Oral Oncol*. 2018;85:68-81.
- 875 73. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray
876 and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
877 *Neoplasia*. 2002;4(4):337-46.
- 878 74. Osmak M. Statins and cancer: current and future prospects. *Cancer Lett*.
879 2012;324(1):1-12.
- 880 75. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and
881 Cancer-Related Mortality. *Physiol Rev*. 2015;95(3):727-48.

882 76. Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes
883 Vasc Dis Re. 2014;11(6):390-4.

884 77. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried
885 W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer
886 Prev Res. 2012;5(11):1260-72.

887 78. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9
888 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.

889

890

891

892

893 **Fig 1.** Forest plot showing the causal effects of *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR*

894 variants on the oral and oropharyngeal cancer subsites in GAME-ON.

895

896



905

906

907


908

909

910


911

912 Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for *LDLR* and *PCSK9* single nucleotide polymorphisms effect on combined oral/ oropharyngeal cancer in GAME-ON.




Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .




Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites

